Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ningmitai + sildenafil
- Development stage
- Unknown
- Lead developer
- Xintian Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ningmitai + sildenafil is a **combination therapy** consisting of Ningmitai capsule, an oral traditional Chinese herbal medicine, and sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor. Ningmitai capsule contains multiple herbal ingredients with anti-inflammatory, analgesic, and immunomodulatory properties, while sildenafil acts by increasing cyclic guanosine monophosphate (cGMP) through inhibition of PDE5, resulting in smooth muscle relaxation and enhanced blood flow. The combination has been studied primarily for treating men with **chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and erectile dysfunction (ED)**, with clinical evidence indicating improved pain reduction and erectile function compared to either component alone, with favorable tolerability and no reported adverse events[2][5][6][7].
- Brand names
- Ningmitai capsule + sildenafil
- Other names
- NMT + sildenafilNingmitai + sildenafil
02
Targets
PDE6 (Phosphodiesterase 6)PDE5 (Phosphodiesterase 5A)
Beyond the preview
Go deeper on ningmitai + sildenafil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ningmitai + sildenafil.